Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Omeprazole drug interaction studies.

T Andersson1

  • 1Department of Clinical Pharmacology, Hässle Research Laboratories, Mölndal, Sweden.

Clinical Pharmacokinetics
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fecal calcium levels of bird nestlings as a potential indicator of species-specific metal sensitivity.

Environmental pollution (Barking, Essex : 1987)·2024
Same author

Histological stroke clot analysis after thrombectomy: Technical aspects and recommendations.

International journal of stroke : official journal of the International Stroke Society·2019
Same author

Correction to: The unexplained success of stentplasty vasospasm treatment : Insights using Mechanistic Mathematical Modeling.

Clinical neuroradiology·2019
Same author

The unexplained success of stentplasty vasospasm treatment : Insights using Mechanistic Mathematical Modeling.

Clinical neuroradiology·2019
Same author

Coffee consumption, genetic susceptibility and risk of latent autoimmune diabetes in adults: A population-based case-control study.

Diabetes & metabolism·2018
Same author

Family history of type 1 and type 2 diabetes and risk of latent autoimmune diabetes in adults (LADA).

Diabetes & metabolism·2017
Same journal

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026
Same journal

Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics.

Clinical pharmacokinetics·2026
Same journal

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same journal

Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing.

Clinical pharmacokinetics·2026
Same journal

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Clinical pharmacokinetics·2026
Same journal

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Clinical pharmacokinetics·2026
See all related articles

Omeprazole minimally affects drug absorption and liver blood flow. It may inhibit metabolism of certain drugs via cytochrome P450 IIC, but overall drug interaction potential is limited.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Drug Interactions

Background:

  • Omeprazole is a widely used proton pump inhibitor.
  • Potential drug interactions with omeprazole are a concern for patient safety.
  • Understanding these interactions is crucial for effective pharmacotherapy.

Purpose of the Study:

  • To review and analyze the literature on drug interactions involving omeprazole.
  • To elucidate the mechanisms underlying potential omeprazole-drug interactions.
  • To assess the clinical significance of observed interactions.

Main Methods:

  • Literature review of studies investigating omeprazole's effects on drug absorption, distribution, metabolism, and excretion.
  • Analysis of data on changes in intragastric acidity, liver blood flow, and cytochrome P450 enzyme activity.

Related Experiment Videos

  • Evaluation of omeprazole's impact on specific drug substrates.

    • Main Results:

    • Omeprazole does not significantly affect the absorption of amoxicillin, bacampicillin, or alcohol.
    • Minor increases in digoxin and nifedipine absorption were observed, likely not clinically significant.
    • Omeprazole does not alter liver blood flow, as evidenced by unchanged indocyanine green elimination and lidocaine clearance.
    • Omeprazole does not induce cytochrome P450 enzymes.
    • Omeprazole can partially inhibit the metabolism of drugs primarily metabolized by cytochrome P450 subfamily IIC (e.g., diazepam, phenytoin).
    • Omeprazole does not inhibit metabolism of drugs metabolized by subfamilies IA, IID, and IIIA.

    Conclusions:

    • Omeprazole's impact on drug absorption and liver function is minimal.
    • The potential for omeprazole to cause clinically significant drug interactions through cytochrome P450 inhibition is limited due to the narrow substrate specificity of affected enzymes.
    • Further research may be warranted for specific drug combinations.
    • Clinicians should be aware of potential interactions with CYP2C19 substrates.